IL297398B1 - Pharmaceutical preparation containing l–triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis - Google Patents

Pharmaceutical preparation containing l–triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis

Info

Publication number
IL297398B1
IL297398B1 IL297398A IL29739822A IL297398B1 IL 297398 B1 IL297398 B1 IL 297398B1 IL 297398 A IL297398 A IL 297398A IL 29739822 A IL29739822 A IL 29739822A IL 297398 B1 IL297398 B1 IL 297398B1
Authority
IL
Israel
Prior art keywords
triiodothyronine
pharmaceutical composition
hours
sepsis
use according
Prior art date
Application number
IL297398A
Other languages
English (en)
Hebrew (he)
Other versions
IL297398A (en
Original Assignee
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Ioulia Tseti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A, Ioulia Tseti filed Critical Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A
Publication of IL297398A publication Critical patent/IL297398A/en
Publication of IL297398B1 publication Critical patent/IL297398B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL297398A 2020-04-21 2021-04-15 Pharmaceutical preparation containing l–triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis IL297398B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (2)

Publication Number Publication Date
IL297398A IL297398A (en) 2022-12-01
IL297398B1 true IL297398B1 (en) 2026-01-01

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297398A IL297398B1 (en) 2020-04-21 2021-04-15 Pharmaceutical preparation containing l–triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis

Country Status (13)

Country Link
US (1) US20230157982A1 (https=)
EP (1) EP4138810A1 (https=)
JP (1) JP2023538984A (https=)
KR (1) KR20230022839A (https=)
CN (1) CN115996710B (https=)
AU (1) AU2021258544A1 (https=)
BR (1) BR112022021250A2 (https=)
CA (1) CA3176106A1 (https=)
GE (2) GEP20247706B (https=)
IL (1) IL297398B1 (https=)
MX (1) MX2022013228A (https=)
WO (1) WO2021214497A1 (https=)
ZA (1) ZA202212502B (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1942995A (en) * 1994-03-15 1995-10-03 K.U. Leuven Research & Development New use of growth hormone
SI3908272T1 (sl) 2019-01-09 2023-07-31 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije

Also Published As

Publication number Publication date
JP2023538984A (ja) 2023-09-13
IL297398A (en) 2022-12-01
WO2021214497A1 (en) 2021-10-28
ZA202212502B (en) 2024-05-30
MX2022013228A (es) 2022-11-14
GEP20247706B (en) 2024-12-10
CA3176106A1 (en) 2021-10-28
AU2021258544A1 (en) 2022-10-27
BR112022021250A2 (pt) 2022-12-06
EP4138810A1 (en) 2023-03-01
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21
CN115996710B (zh) 2024-06-28
KR20230022839A (ko) 2023-02-16
US20230157982A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
Joannidis et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: expert opinion of the working group for nephrology, ESICM
Brochard et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine
Heather et al. Isoproterenol induces in vivo functional and metabolic abnormalities; similar to those found in the infarcted rat heart
Avendano et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation.
Westphal et al. Hydroxyethyl starches: different products–different effects
US6221851B1 (en) Pharmaceutical therapy for congestive heart failure
Lin et al. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia
US11213514B2 (en) Alpha-1-adrenergic receptor agonist therapy
JP2014514310A (ja) 毛細血管漏出の予防及び治療のために手術時に投与されるプロスタサイクリン及びその類似体
BR112013000744A2 (pt) uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
AU2015258805B2 (en) Compositions and methods of treating cardiac fibrosis with ifetroban
Ikeda et al. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters
Bersten et al. Respiratory mechanics and surfactant in the acute respiratory distress syndrome
WO2020256905A1 (en) Composition for and method of treating hepatic tissue injury
US20230157982A1 (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis
Guillamet et al. Cardiovascular management of septic shock in 2012
EA048898B1 (ru) Фармацевтическая композиция, содержащая l-трийодтиронин (т3), для применения при лечении тканевой гипоксии и сепсиса
HK40088108A (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
HK40088108B (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
Ishihara Kidney function after the intraoperative use of 6% tetrastarches (HES 130/0.4 and 0.42)
GR1010261B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
WO2007129618A1 (ja) 好中球の活性化および遊走因子の抑制剤およびその利用
Nugent et al. Low-volume resuscitation with VS-101, a next-generation PEGylated HBOC, improves survival after severe hemorrhagic shock in rats
GR1010182B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
JP2003527420A (ja) 鬱血性心不全の治療方法